Please use this identifier to cite or link to this item: https://repository.cihe.edu.hk/jspui/handle/cihe/4540
DC FieldValueLanguage
dc.contributor.authorChan, Stella Sze Waen_US
dc.contributor.authorLu, Zengbing-
dc.contributor.otherNgan, M. P.-
dc.contributor.otherLiu, J. Y. H.-
dc.contributor.otherYang, L.-
dc.contributor.otherTu, L.-
dc.contributor.otherGiuliano, C.-
dc.contributor.otherLovati, E.-
dc.contributor.otherPietra, C.-
dc.contributor.otherRudd, J. A.-
dc.date.accessioned2025-02-28T03:30:55Z-
dc.date.available2025-02-28T03:30:55Z-
dc.date.issued2024-
dc.identifier.urihttps://repository.cihe.edu.hk/jspui/handle/cihe/4540-
dc.description.abstractThis study investigated whether ghrelin mimetics, namely anamorelin and ipamorelin, can alleviate weight loss and inhibition of feeding observed during acute and delayed phases of cisplatin-induced emesis in ferrets. The potential of anamorelin to inhibit electrical field stimulation (EFS)-induced contractions of isolated ferret ileum was compared with ipamorelin. In other experiments, ferrets were administered anamorelin (1–3 mg/kg), ipamorelin (1–3 mg/kg), or vehicle intraperitoneally (i.p.) 30 s before cisplatin (5 mg/kg, i.p.) and then every 24 h, and their behaviour was recorded for up to 72 h. Food and water consumption was measured every 24 h. The effect of anamorelin (10 µg) was also assessed following intracerebroventricular administration. Anamorelin and ipamorelin inhibited EFS-induced contractions of isolated ileum by 94.4 % (half-maximal inhibitory concentration [IC<sub>50</sub>]=14.0 µM) and 54.4 % (IC<sub>50</sub>=11.7 µM), respectively. Neither of compounds administered i.p. had any effect on cisplatin-induced acute or delayed emesis, but both inhibited associated cisplatin-induced weight loss on the last day of delayed phase (48–72 h) by approximately 24 %. Anamorelin (10 µg) administered intracerebroventricularly reduced cisplatin-induced acute emesis by 60 % but did not affect delayed emesis. It also improved food and water consumption by approximately 20 %–40 % during acute phase, but not delayed phase, and reduced associated cisplatin-induced weight loss during delayed phase by ∼23 %. In conclusion, anamorelin and ipamorelin administered i.p. had beneficial effects in alleviating cisplatin-induced weight loss during delayed phase, and these effects were seen when centrally administered anamorelin. Anamorelin inhibited cisplatin-induced acute emesis following intracerebroventricular but not intraperitoneal administration, suggesting that brain penetration is important for its anti-emetic mechanism of action.en_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.ispartofPhysiology & Behavioren_US
dc.titleThe growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanismen_US
dc.typejournal articleen_US
dc.identifier.doi10.1016/j.physbeh.2024.114644-
dc.contributor.affiliationS.K. Yee School of Health Sciencesen_US
dc.relation.issn1873-507Xen_US
dc.description.volume284en_US
dc.cihe.affiliatedYes-
item.languageiso639-1en-
item.grantfulltextopen-
item.fulltextWith Fulltext-
item.cerifentitytypePublications-
item.openairecristypehttp://purl.org/coar/resource_type/c_6501-
item.openairetypejournal article-
crisitem.author.deptS.K. Yee School of Health Sciences-
crisitem.author.deptS.K. Yee School of Health Sciences-
Appears in Collections:HS Publication
Files in This Item:
File Description SizeFormat
View Online132 BHTMLView/Open
SFX Query Show simple item record

Google ScholarTM

Check

Altmetric

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.